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Vaccine safety signals require investigation, which may be done rapidly at the population
level using ecological studies, before embarking on hypothesis-testing studies. Incidence
rates were used to assess a signal of narcolepsy following AS03-adjuvanted monovalent
pandemic H1N1 (pH1N1) influenza vaccination among children and adolescents in Sweden
and Finland in 2010. We explored the utility of ecological data to assess incidence of narco-
lepsy following exposure to pandemic H1N1 virus or vaccination in 10 sites that used differ-
ent vaccines, adjuvants, and had varying vaccine coverage.
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Methods
We calculated incidence rates of diagnosed narcolepsy for periods defined by influenza
virus circulation and vaccination campaign dates, and used Poisson regression to estimate
incidence rate ratios (IRRs) comparing the periods during which wild-type virus circulated
and after the start of vaccination campaigns vs. the period prior to pH1N1 virus circulation.
We used electronic health care data from Sweden, Denmark, the United Kingdom, Canada
(3 provinces), Taiwan, Netherlands, and Spain (2 regions) from 2003 to 2013. We investi-
gated interactions between age group and adjuvant in European sites and conducted a sim-
ulation study to investigate how vaccine coverage, age, and the interval from onset to
diagnosis may impact the ability to detect safety signals.
Results
Incidence rates of narcolepsy varied by age, continent, and period. Only in Taiwan and Swe-
den were significant time-period-by-age-group interactions observed. Associations were
found for children in Taiwan (following pH1N1 virus circulation) and Sweden (following vac-
cination). Simulations showed that the individual-level relative risk of narcolepsy was under-
estimated using ecological methods comparing post- vs. pre-vaccination periods; this effect
was attenuated with higher vaccine coverage and a shorter interval from disease onset to
diagnosis.
Conclusions
Ecological methods can be useful for vaccine safety assessment but the results are influ-
enced by diagnostic delay and vaccine coverage. Because ecological methods assess risk
at the population level, these methods should be treated as signal-generating methods and
drawing conclusions regarding individual-level risk should be avoided.
Introduction
In August 2010, a safety signal of narcolepsy following AS03-adjuvanted pdm(09)H1N1 influ-
enza vaccine Pandemrix1 was reported in Finland and Sweden among children and adoles-
cents [1]. Other rapid risk assessment studies conducted in the European Union (EU) did not
show changes in incidence rates of narcolepsy diagnoses, except in Finland, Sweden, and Nor-
way [2], all countries that achieved high coverage rates with Pandemrix. Subsequent hypothe-
sis-testing studies showed associations; these had high within- and between-study variation
[3]. In China, where vaccine coverage was very low, a 3-fold increase in narcolepsy onset was
reported following the peak of the pandemic [4].
Narcolepsy is a rare disease with a long interval from onset of symptoms to diagnosis, espe-
cially in adults. Several possible explanations for the purported pdm(09)H1N1 and narcolepsy
link have been proposed but none confirmed. Hypotheses range from a causal effect of the
AS03 adjuvant, the manufacturing process, presence of nucleoproteins in Pandemrix, and
molecular mimicry, to awareness and assessment biases, and residual confounding [5–10].
Based upon simulation studies conducted by Wijnans et al., in the absence of a causal associa-
tion but in the presence of accelerated diagnosis due to awareness, we would expect to see an
increased incidence of narcolepsy diagnosis following awareness of the association followed by
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introduccion) based on regional government
resolutions dated October 15, 2009, and February
6, 2012. Data are available from Rube´n Vega
(vega_rub@gva.es) who holds the position of data
manager at FISABIO. SIDIAP: Data from Catalunya,
Spain, are restricted due to regulations intended to
protect personal patient information. These
restrictions are imposed by the Information
System for Research in Primary Care (SIDIAP)
(http://www.sidiap.org/index.php/en) and the Ley
Orga´nica 15/1999, de 13 de diciembre, de
Proteccio´n de Datos de Cara´cter Personal (LOPD)
(https://www.boe.es/buscar/doc.php?id=BOE-A-
1999-23750). Data are available from Eduardo
Hermosilla (ehermosilla@idiapjgol.info), data
manager at SIDIAP. Sweden: The data underlying
the findings is applied to access restrictions
according to Swedish law, thus the authors are not
able to make the dataset publicly available. The
data used in this study are owned by Statistics
Sweden (SCB), and the Swedish National Board of
Health and Welfare (Socialstyrelsen). Any
researchers, including international researchers,
who are interested in obtaining the data can
contact SCB via information@scb.se, and
Socialstyrelsen via registerservice@socialstyrelsen.
se. One can visit https://www.scb.se/sv_/Vara-
tjanster/Bestalla-mikrodata/ (SCB), and http://www.
socialstyrelsen.se/register/bestalladatastatistik/
bestallaindividuppgifterforforskningsandamal
(Socialstyrelsen) fordetailed information about how
to apply for access to register data for research
purposes. Denmark: Data from Denmark, which
are owned by the National Board of Healthcare
Data (forskerservice@sundhedsdata.dk), are
restricted due the content of sensitive information.
These restrictions are imposed by the Danish Data
Protection Board. Manitoba: Manitoba data used in
this article was derived from administrative health
and social data as a secondary use. The data was
provided under specific data sharing agreements
only for approved use at MCHP. The original
source data is not owned by the researchers or
Manitoba Centre for Health Policy (MCHP) and as
such cannot be provided to a public repository.
Where necessary, source data specific to this
article or project may be reviewed at MCHP with
the consent of the original data providers, along
with the required privacy and ethical review bodies.
All correspondence relating to MCHP repository
access should be sent to MCHP_Access@cpe.
a decrease, even to levels below the background incidence, due to depletion of cases[8]. This
effect may be particularly important in conditions with a long delay to diagnosis such as in
narcolepsy where the delay in diagnosis from initial symptoms can be 10–20 years [11].
The SOMNIA (Systematic Observational Method for Narcolepsy and Influenza Immuniza-
tion Assessment) study was funded by the US Centers for Disease Control and Prevention
(CDC) and used information from countries that used different types of adjuvanted pandemic
influenza vaccines to assess whether the pdm(09)H1N1 influenza vaccine and specifically the
MF59 and AS03 adjuvants were associated with narcolepsy.
One of the goals of SOMNIA was to assess patterns of incidence rates of narcolepsy in mul-
tiple geographic areas and to understand changes in incidence rates of narcolepsy diagnoses
before, during, and after the pdm(09)H1N1 influenza pandemic by using electronic health
care data, which may be rapidly available. In this paper, we explore whether assessment of
safety signals based on ecological methods and population-based electronic health care data
are suitable for vaccine safety risk assessment, by exploiting the heterogeneity in vaccine cover-
age, types of vaccines, and vaccination programs across countries. We assess what strength of
signals can be detected using population-level data collected before and after a hypothetical
targeted vaccination campaign.
Ecological studies can be defined as those that measure exposure and outcomes at the
group level rather than at the individual level [12, 13]. In such a study, groups are defined by a
naturally occurring difference in space or time such as a change in the vaccination schedule
[14] or the beginning and end of a targeted vaccination campaign [15].
This study may serve as an example of the utility of ecological methods to assess vaccine
safety signals, particularly regarding events with long onset-to-diagnosis intervals.
Materials and methods
Narcolepsy diagnosis incidence rates were evaluated in ten sites representing seven countries
spanning three continents (Taiwan (TW), Canada (CA) [Manitoba, Alberta, and British
Columbia], The Netherlands (NL), The United Kingdom (UK), Sweden (SE), Denmark (DK),
and Spain (ES) [Valencia and Cataluña]) using population-based electronic healthcare data-
bases originating from general practitioners (GPs) (UK, ES, NL) or claims/record linkage data-
bases (SE, DK, TW [16–18], and CA) (S1 Table).
Study population and follow-up
For data sources in which individual linkage can be made between population and diagnoses
(all sites except Sweden and British Columbia, Canada), the study population comprised all
individuals registered within each of the databases during the study period. Observation time
began on the date of first registration of an individual in the database, the start of the study
period (January 2003), or the start date of data collection for the database, whichever was the
latest and ended on the date of death, the date registration was terminated, the end of data col-
lection, or the end of the study period (December 2013), whichever was the earliest. Sweden
and British Columbia, Canada used census data to calculate person-time denominators. We
used a harmonized approach in which databases locally extracted their data into simple input
files in a common format that could be locally analyzed and aggregated using SAS or JAVA-
based software [2, 19].
Case identification and validation
Cases were persons with a new diagnosis of narcolepsy with or without cataplexy. Validation
of the diagnostic codes using patient discharge letters and medical records was conducted in
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umanitoba.ca. Alberta: Data from Alberta Canada
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Government of Alberta. Data access requests may
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potentially sensitive and confidential information.
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Welfare Data Science Center (HWDC), Ministry of
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of HWDC Executive Officer. THIN: For the UK, Data
have been accessed from The Health Information
Network (THIN) database, which requires protocol
approval as well as payment of a licensing fee
before data can be accessed. We confirm that
interested and qualified researchers can access the
data in the same manner by which the authors
obtained it by contacting hbhullar@uk.imshealth.
com. British Columbia: There was no requirement
to inform patients given the de-identification of the
provincial health data that was provided. BC data
has been provided in aggregate format. There are
no privacy issues concerning the data provided by
BC Ministry of Health for this study. Data are
available from Cornel Lencar, Senior Health Data
Request Officer, British Columbia Ministry of
Health Cornel.Lencar@gov.bc.ca. All inferences,
opinions, and conclusions drawn in this publication
are those of the author(s), and do not necessarily
reflect the opinions or policies of the British
Columbia Ministry of Health. The Netherlands: The
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and is supervised by a Governance board. The
dataset cannot be made publically available. The
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Medical Centre in Rotterdam, The Netherlands. Any
researcher, including international researchers,
who are interested in using the data can contact
Erasmus Medical Centre via ipci@erasmusmc.nl.
Funding: The study is funded by the Centers for
Disease Control and Prevention (CDC), Atlanta,
USA, under CDC contract number 200-2012-
53425_addendum 0001 to SB. The CDC website is:
https://www.cdc.gov/. The funders participated in
design of the study but had no role in data
collection, analysis, decision to publish, or
preparation of the manuscript.
Competing interests: MGS, as an employee of
IDIAP Jordi Gol, worked on projects funded by
pharmaceutical companies unrelated to this study.
RM, as an employee of IDIAP Jordi Gol, worked on
the GP databases in the Netherlands and Valencia, Spain. For these two sites, only validated
cases were used in the analysis. The other sites used algorithms combining diagnostic codes
for narcolepsy with claims for multiple sleep latency tests (MSLTs) to reduce the false positive
rate. The same method was used at each site over the entire time period. No further validation
was done in other sites (S1 Table).
Analysis
To investigate the purported narcolepsy-pandemic vaccine effect, incidence rates of narcolepsy
diagnosis were calculated by calendar year and month and also categorized into three periods
based on specific circulation/vaccination periods in each country: 1) pre-pandemic (from Jan-
uary 2003 until the start of the period of pH1N1 circulation); 2) during pH1N1 wild-type virus
circulation until the start of the country’s pH1N1 vaccination campaign; and 3) from the start
of the pH1N1 influenza vaccination campaign through the end of the study (S1 Table). Pan-
demic H1N1 virus circulation was defined as the period during which weekly influenza test
positivity for pH1N1 infection exceeded 10%. Dynamic age groups were categorized as<5
years, 5–19 years, 20–59 years, and�60 years at the time of diagnosis. This categorization was
motivated by differences in diagnosis for each age group, and particularly the challenges of dif-
ferential diagnosis in young children and the elderly [20, 21]. Incidence rates of narcolepsy
diagnoses were calculated by dividing the number of narcolepsy cases by the accumulated per-
son-time. Ninety-five percent confidence intervals (CIs) were calculated assuming a negative
binomial distribution. Following confirmation of homogeneity in incidence rates among data-
bases within the same country, further analyses were conducted at the level of the country
rather than the site.
Within each country, we estimated incidence rate ratios (IRRs) and 95% CIs for each time
period using Poisson regression, with the pre-circulation period as a reference. We included
terms for age strata, time periods, and an age�time period interaction using time periods as
defined by pH1N1 circulation and vaccination campaign dates.
We conducted additional analyses restricted to European countries to estimate the impact
of vaccine coverage and adjuvant among children and adolescents and separately among
adults. For this analysis, a composite variable summarizing vaccine coverage classified as low
(<20%) or high (�20%) and adjuvant (MF59 or AS03) was created, and incidence in the
period after vaccination had started was compared to the pre-pH1N1 circulation period.
Because the composite adjuvant/coverage variable was collinear with database and country,
neither database nor country was included in the European model.
Simulation
To better understand the utility of ecological methods for assessing vaccine safety signals and
whether an association in one age group may be masked in a population-level analysis, we con-
ducted statistical simulations. Each set consisted of 10,000 subjects aged 0 to 100 years, who
were observed in the period January 1, 2003 to December 31, 2012. The period of the vaccina-
tion campaign was set from October to December 2009. In each simulated data set, vaccine
coverage during this period was set at one out of 9 different values between 1 and 99 percent
(see Table 1). Subjects assigned as vaccinated got a vaccination date during the campaign
period. Baseline narcolepsy incidence was simulated based on reported estimates of incidence
by decade of age [22].For vaccinated persons aged<20 years, during the six months following
vaccination, the risk for narcolepsy onset was simulated using a relative risk varying from 0.5
to 10 compared to the baseline incidence. In subjects aged�20 years no increased risk was
applied. The median time from onset to diagnosis was initially set at 4 years for adults and at
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1.5 years for children (aged�18 years) based on SOMNIA data (not shown). The effect of the
length of the interval from onset to diagnosis was also tested by varying a reduction rate
parameter, with 0 removing the interval (i.e. immediate diagnosis following onset), 0.5 halving
the interval, and 1 retaining the full simulated interval (see Table 1 for description of simula-
tion parameters). Finally, in part of the sets the full 10 years was used as study period, in the
others it was restricted to 6 months after the end of the vaccination campaign (7.5 years).
For each set of simulation parameters, 500 replications were run. The population-level inci-
dence rate ratio for the period following the vaccination campaign vs. the period prior to the
vaccination campaign was estimated using Poisson regression. The median incidence rate
ratio from the 500 replications was calculated overall and by age group, and plotted against
vaccine coverage. The percentage bias was calculated by subtracting the simulated relative risk
from the estimated IRR and dividing by the simulated IRR.
Calibration
Using the simulation results, a model was constructed to determine how the underlying indi-
vidual-level relative risk was related to the median estimated IRR and the appointed vaccine
coverage and interval reduction, and the interaction of these terms (Model: Simulated individ-
ual-level true RR = Estimated IRR + Simulated vaccine coverage + Simulated onset-to-diagno-
sis reduction + Interactions). This model was then applied to results obtained from the
observed data, using the IRR found in the SOMNIA study and the relevant vaccine coverage
and diagnostic delay (S1 Table), in order to calculate the underlying relative risks in 5- to
19-year olds, that would have been necessary to produce this IRR in the absence of other
sources of bias. This calibration was restricted to the 5–19 year age group as this group was the
source of the safety signal and the only subjects for whom an increased risk was simulated.
This study was conducted under the principles of the Helsinki declaration and each site was
responsible for obtaining appropriate ethical approvals. The overall study was approved by the
Institutional Review Board at Cincinnati Children’s Hospital, Cincinnati, Ohio, USA. The
study was also approved at each site by the following bodies: Health Research Ethics Board,
Alberta, Canada; University of Manitoba Research Ethics Board, Manitoba, Canada; Ethics
Committee for Clinical Research of the Directorate General of Public Health and Center for
Advance Research in Public Health (CEIC DGSP/CSISP), Valencia, Spain; Comitè E`tic d’In-
vestigacio´ de l’IDIAP Jordi Gol, Cataluña, Spain; Regional Ethics Review Board, Stockholm,
Sweden; The Institutional Review Board of Centers for Disease Control, Ministry of Health
and Welfare, Taiwan; THIN Scientific Review Committee, United Kingdom; Erasmus Medical
Center Medical Internal Review Board, The Netherlands. Due to use of aggregate data, British




Probability of vaccination .01, .05, .10. .25, .50, .75, .95, .99
Relative Risk Relative risk of narcolepsy onset in the
first 6 months after vaccination
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Interval
Reduction Rate
Reduction of onset-to-diagnosis interval 0: Immediate diagnosis following onset
0.5: Halving of the onset-to-diagnosis interval
1: Full onset-to-diagnosis interval
Observation
Length
Total length of observation time following
start of observation in January 2003
2739 days: pre-vaccination campaign time + 90
days vaccination campaign + 6 month risk period
3625 days: 10 years
https://doi.org/10.1371/journal.pone.0204799.t001
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Columbia, Canada and Denmark conducted the study under rolling approval and study-spe-
cific approval was not sought.
Results
Observed incidence
Incidence rates of narcolepsy diagnoses ranged from 0.22 to 1.52 per 100,000 person-years by
site (Table 2). Incidence rates in databases within the same country (Canada and Spain) were
similar so for further analysis country-specific data were pooled.
Due to very low rates observed among the very young (<5 years) and the elderly (�60
years) (S2 Table) and known difficulties in diagnosis in these age groups, these were not
included in further analyses. In Fig 1, IRs are shown stratified by age group and time period.
In investigation of age group and time period and the interaction of these factors, IRRs were
significantly elevated in both age groups in Taiwan (where MF59-adjuvanted vaccine coverage
was 59% for those<19 years and 11% for those�19 years) in the period during circulation of
wild-type virus prior to vaccination. For those aged 5–19 years, the IRR was 2.50 (95%CI 1.46,
4.28), and for those aged 20–59 years, the IRR was 2.23 (95%CI 1.26, 3.94). This continued in
the period after the vaccination campaign had started, with IRR 1.60 (95%CI 1.20, 2.13) for
those aged 5–19 years and IRR 2.13 (95%CI 1.62, 2.79) for those aged 20–59 years (Table 3). In
Sweden, where AS03-adjuvanted Pandemrix vaccine coverage was 60%, in the period after
vaccination incidence rates among those aged 5–19 years and 20–59 years were elevated
[IRR = 9.01 (95%CI 6.89, 11.80) and IRR = 1.69 (95%CI 1.46, 1.95)], respectively (Fig 1 &
Table 3). None of the other countries showed significant time-period-by-age-group
interactions.
In the analysis restricted to Europe and including a vaccine coverage/adjuvant composite
variable, IRRs were elevated in the period following start of vaccination in the high-coverage
AS03 (Sweden) and low-coverage AS03 groups for children and adolescents (S3 Table). In
adults, an elevated incidence in the period following vaccination was detected in the AS03
high-coverage group, which was limited to Sweden. In this analysis, no changes in the inci-
dence of narcolepsy in the post-vaccination period were seen in sites using MF59-adjuvanted
vaccine, all of which had low coverage (S3 Table).
Table 2. Crude incidence rates by site.
Site Period Events Person-years IR
EU
Denmark 2003–2013 269 17,850,129 1.50 (1.33–1.69)
United Kingdom 2003–2013 467 42,897,721 1.09 (0.99–1.19)
ES, Valencia (validated) 2009–2013 46 20,458,082 0.22 (0.17–0.28)
ES, Cataluña 2007–2013 240 34,861,809 0.69 (0.50–0.78)
Sweden 2003–2013 1536 102,027,209 1.52 (1.43–1.59)
The Netherlands (validated) 2003–2013 14 2,879,712 0.49 (0.29–0.76)
North America
CA, British Columbia 2003–2013 278 47,857,684 0.58 (0.32–0.64)
CA, Alberta 2003–2013 427 51,885,946 0.82 (0.74–0.90)
CA, Manitoba 2003–2010 42 6,335,257 0.66 (0.50–0.86)
Asia
Taiwan 2003–2012 472 161,407,503 0.29 (0.27–0.32)
Abbreviations: IR (Incidence Rate), EU (European Union), ES (Spain), CA (Canada)
https://doi.org/10.1371/journal.pone.0204799.t002
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Simulation
The simulation study showed that in an analysis such as the one described above, the true RR
is consistently underestimated when it is greater than one and overestimated when less than
one (Fig 2). Underestimation of true relative risks greater than one is attenuated as vaccination
coverage increases but the estimate remains about 6%-26% too low even with vaccination cov-
erage as high as 99% with no delay from onset to diagnosis and a 10-year observation period
(Fig 3). As the interval from onset to diagnosis increases, the estimated relative risk deviates
further from the true relative risk; performance is improved if the observation time captures
only the period of increased risk (data not shown). When the time from onset to diagnosis was
not reduced no increased risk was detected for any set of simulation parameters (data not
shown). Stratification by age group was effective in elucidating the group that was the source
of the increased risk.
Calibration
When using a model derived from the results of the simulation study to predict which should
have been the true (calibrated) IRR to produce the estimates found in the SOMNIA study,
these true IRRs were always considerably higher than the estimates. Notably, according to the
model, the required individual-level relative risk underlying a 9-fold IRR which was found in
5–19 year olds in Sweden should have been 36.04 (95% CI: 27.79, 46.90) (Table 4).
Fig 1. Incidence rates (with 95% CIs) of narcolepsy pre-circulation and post-vaccination in children (05–19 yrs.) and adults (20–59 yrs.).
https://doi.org/10.1371/journal.pone.0204799.g001
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Table 3. IRs and IRRs by country, age and period.
Site Age Period� Cases Person
years
IR IRR† 95%CI
United Kingdom 5–19 Pre-Circulation 26 4247239 0.61 Ref —
Circulation 0 229303 0.00 NA —
Vaccination & Post 28 2752486 1.02 1.66 0.97, 2.83
20–59 Pre-Circulation 183 13782669 1.33 Ref —
Circulation 9 744620 1.21 0.91 0.47, 1.78
Vaccination & Post 90 8706262 1.03 0.78 0.61, 1.00
Denmark 5–19 Pre-Circulation 26 1941950 1.34 Ref —
Circulation 3 160562 1.87 1.40 0.42, 4.61
Vaccination & Post 28 1352428 2.07 1.55 0.91, 2.64
20–59 Pre-Circulation 103 5258884 1.96 Ref —
Circulation 8 416864 1.92 0.98 0.48, 2.01
Vaccination & Post 58 3492758 1.66 0.85 0.62, 1.17
The Netherlands 5–19 Pre-Circulation 2 103950 1.92 Ref
Circulation 0 29453 0.00 NA
Vaccination & Post 1 394895 0.25 0.13 0.01, 1.45
20–59 Pre-Circulation 2 306773 0.65 Ref
Circulation 1 87315 1.15 1.76 0.16, 19.37
Vaccination & Post 7 1144346 0.61 0.94 0.20, 4.52
Spain 5–19 Pre-Circulation 7 1617473 0.43 Ref
Circulation 4 1488771 0.27 0.62 0.18, 1.13
Vaccination & Post 26 4715178 0.55 1.27 0.55, 2.94
20–59 Pre-Circulation 48 6847254 0.70 Ref —
Circulation 33 610444 0.54 0.77 0.50, 1.20
Vaccination & Post 125 18915104 0.27 0.94 0.68, 1.31
Sweden 5–19 Pre-Circulation 62 10381883 0.60 Ref —
Circulation 1 819877 0.12 0.20 0.03, 1.47
Vaccination & Post 369 6854603 5.38 9.01 6.89, 11.80
20–59 Pre-Circulation 338 29823712 1.13 Ref —
Circulation 26 2418238 1.08 0.95 0.64, 1.41
Vaccination & Post 401 20992445 1.91 1.69 1.46, 1.95
Canada 5–19 Pre-Circulation 67 10107116 0.66 Ref —
Circulation 6 1261204 0.48 0.72 0.31, 1.70
Vaccination & Post 53 6378494 0.83 1.25 0.87, 1.80
20–59 Pre-Circulation 265 34413993 0.77 Ref —
Circulation 36 4574717 0.79 1.02 0.72, 1.45
Vaccination & Post 182 24228401 0.75 0.98 0.81, 1.18
Taiwan 5–19 Pre-Circulation 81 13985353 0.58 Ref —
Circulation 16 1103680 1.45 2.50 1.46, 4.28
Vaccination & Post 110 11867183 0.93 1.60 1.20, 2.13
20–59 Pre-Circulation 78 46806947 0.17 Ref —
Circulation 14 3768896 0.37 2.23 1.26, 3.94
Vaccination & Post 158 44542437 0.35 2.13 1.62, 2.79
�Periods are as follows: Pre-Circulation = January 2003-the beginning of wild-type H1N1 circulation (defined per country); Circulation = Period from the beginning of
wild-type H1N1 circulation until the start of the vaccination campaign (defined per country); Vaccination & Post = Period from the beginning of the vaccination
campaign through December 2013.
† IRR comparing the period to the pre-circulation period, within the age group
https://doi.org/10.1371/journal.pone.0204799.t003
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Discussion
Evaluation of incidence rates on a population level can be done relatively quickly in countries/
regions with accessible population-based electronic health care databases. This is useful for
assessing potential vaccine safety signals. In order to calculate rates quickly in a standardized
manner, harmonization of data into simple input files in a common format allowed for the
pooling and sharing of data across three continents. The method was capable of identifying the
signal in Sweden in 5- to 19-year olds.
In the analysis by country, elevated rates of narcolepsy were only detected in Taiwan during
wild-type virus circulation through the period following vaccination with MF59-adjuvanted
and non-adjuvanted vaccines, and in Sweden following vaccination with AS03-adjuvanted
vaccines. The finding in Taiwan may be due to circulation of wild-type influenza virus prior to
the start of the vaccination campaign [17]. This is consistent with the finding of a 3-fold
increase in narcolepsy onset in China following the peak of the pH1N1 pandemic in a popula-
tion with very low vaccine coverage [4]. Taiwan vaccinated children aged <1 year with
Fig 2. IRR estimates in simulated data, immediate diagnosis (interval reduction rate = 0). Population-level incidence rate ratio estimated from
simulated data with observation time equal to 3625 days and true individual-level relative risk equal to .05, 1, 2, 5, or 10 (columns). Gray horizontal
reference lines represent the true simulated individual-level relative risk of narcolepsy diagnosis. The interval reduction rate parameter is set equal to
zero (meaning immediate diagnosis following onset of symptoms). Vaccination coverage increases within each column along the x-axis. Colored lines
represent age group-specific IRRs as noted in the legend and colored bands represent associated 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0204799.g002
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MF59-adjuvanted vaccine and adults and school children with mainly non-adjuvanted vac-
cine. In Sweden, where the signal of a narcolepsy safety concern was originally detected [23]
and where patients diagnosed with narcolepsy are being compensated [7], rates were much
higher than in the other countries. This could be due to differential reporting due to increased
awareness of the putative association, a true causal effect in this population with this vaccine,
Fig 3. Percent bias of IRR estimates in simulated data, immediate diagnosis (interval reduction rate = 0). Population-level percent bias estimated
from simulated data with observation time equal to 3625 days and true individual-level relative risk equal to .05, 1, 2, 5, or 10 (columns). The (interval
reduction rate parameter is set equal to zero (meaning immediate diagnosis following onset of symptoms). Vaccination coverage increases within each
column along the x-axis. Colored lines represent age group-specific bias as noted in the legend.
https://doi.org/10.1371/journal.pone.0204799.g003
Table 4. IRRs calibrated using model derived from simulated data.
Country Age Group Observed Ecological IRR 95% CI Gamma Scale Vaccine Coverage Calibrated IRR 95% CI
UK 5–19 1.66 0.97, 2.83 1 .05 7.76 4.95, 12.53
Denmark 5–19 1.55 0.91, 2.64 1 .05 7.31 4.71, 11.76
Netherlands 5–19 0.13 0.01, 1.45 1 .1 1.64 1.16, 6.84
Spain 5–19 1.27 0.55, 2.94 1 .05 6.17 3.24, 12.98
Sweden 5–19 9.01 6.89, 11.80 0.5 .12 36.04 27.79, 46.90
Canada 5–19 1.25 0.87, 1.80 1 .35 5.87 4.62, 7.68
Taiwan 5–19 1.60 1.20, 2.13 0 .65 2.75 1.75, 4.07
https://doi.org/10.1371/journal.pone.0204799.t004
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or some combination of these factors. As shown in simulations, reduction in the time from
onset to diagnosis due to awareness of an association can lead to artificial inflations in risk esti-
mates [8]. In Canadian provinces, with around 40% vaccine coverage of a different AS03-adju-
vanted vaccine (ArepanrixTM), no effect was seen in any of the age groups or periods. This
study, which is by necessity observational, has several limitations. Data were collected accord-
ing to a shared protocol but using locally derived algorithms, which may have led to differences
in sensitivity and specificity. Case validation in some sites revealed low specificity of the origi-
nal extraction, which may be the case in other sites as well. In our analysis by adjuvant and vac-
cine coverage, high coverage with AS03-containing vaccine was only present in Sweden,
making Sweden and this adjuvant/coverage group collinear. This makes it impossible to deter-
mine whether we are seeing the effects of the vaccine itself or of the reporting and detection
patterns in each country. Additionally, the manufacturing process of ArepanrixTM differed
from that of PandemrixTM, leading to vaccines containing different quantities of influenza
virus components [24]. The potential effects of these differences in manufacturing cannot be
differentiated from adjuvant specific-effects or from other country-specific effects using an
ecological design such as the one presented here. Similarly, the countries in which MF59 was
used were the same countries in which case validation was conducted. This limits comparabil-
ity between these countries and others and, therefore, between MF59-containing vaccines and
other pandemic vaccines.
Differences in case ascertainment could also have impacted our estimates. For example, it
has been noted elsewhere that the safety signal originated in Sweden and that this, together
with compensation for cases, may have impacted diagnosis patterns [6, 7]. Additionally, due to
the healthcare system in Taiwan, children complaining of excessive daytime sleepiness are
seen by a specialist quickly, making the interval from onset to diagnosis for these children
shorter. A median time from symptom onset to MSLT referral of 60 days has been reported
for pediatric narcolepsy cases in Taiwan[25]. While it is not possible to rule out a causal associ-
ation, it is important to note that these factors undoubtedly contributed to the estimates
obtained in this study. Differences in the prevalence of the underlying HLA-DQB1�06:02 risk
allele for narcolepsy, which has been reported to vary widely by country, may affect the inci-
dence at the population level but is unlikely to have affected relative risk estimates [26–30].
Ecological methods, when applied to assessment of a signal association with a targeted vac-
cination campaign and a disease with a potentially long interval from onset to diagnosis, can
provide an unbiased estimate of vaccine-associated risk in a very limited set of circumstances.
Obtaining an unbiased estimate in the absence of an association is possible even with very low
vaccine coverage and a long onset to diagnosis interval. However, in the presence of a true vac-
cine-associated risk, all estimates will be biased toward one; this bias is reduced when cases are
detected quickly and vaccination coverage is high. Based upon simulations, the estimates we
obtained in the current study appear to be underestimations of true relative risks greater than
one. However, the simulations did not take into account the possibility of increased reporting
due to an awareness of the association, which has been shown in previous simulations to
inflate risk estimates [8].
The predicted underlying individual-level relative risk obtained using models derived from
simulated data, given the low vaccine coverage attained in most sites, are remarkably high. It is
very unlikely that the true relative risk in Sweden, for example, is 36-fold. Calibrated estimates
for The United Kingdom, however, are only slightly lower than those reported by Miller et al
in their study of narcolepsy following PandemrixTM vaccination in children aged 4–18 [31]. In
general, these predicted relative risks are not in line with results found in the case-control
study conducted within SOMNIA, in which no increased risk following pH1N1 vaccines was
detected [32, 33]. It is important to note that while the case-control data in the SOMNIA study
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did not include any pediatric cases exposed to PandemrixTM, the case-coverage sub-study of
pediatric cases in The Netherlands did not find an association with PandemrixTM [33]. These
inconsistencies may be an illustration of the ecological fallacy, namely that associations
detected at the population level may not be causal at the individual level [34]. In fact, as cover-
age in our simulations approached 100%, our population-level analysis also approached an
individual-level analysis with accurate exposure data for all subjects, explaining why increased
vaccine coverage in simulations leads to more accurate estimates of the simulated relative risk.
Previous simulations have shown that reduction in the time from onset to diagnosis follow-
ing awareness of an association increase risk estimates [8]. Our simulation did not take into
account factors that may have changed over the course of the study period such as awareness
of narcolepsy and of the pH1N1-narcolepsy association as well as changes in diagnostic and
coding practices. Each of these likely contributed to the IRR estimates we obtained. What our
simulations do show is that in the absence of factors that increase case detection in the post-
exposure period, detection of increased population-level risk of a disease with a long onset to
diagnosis interval using ecological methods requires an extreme underlying individual-level
risk.
The ecological approach fails to detect any increased risk unless the time from onset to diag-
nosis is short and both coverage and the true relative risk are high. Because of this, we recom-
mend that population-level methods be used in assessment of outcomes with a delay from
onset to diagnosis only to generate hypotheses or to strengthen signals when population-level
exposure is high. Analysis of the full population when increased risk is only present in one age
stratum performs as well as stratified analysis in terms of the magnitude of risk detected, but
fails to identify the source of the increased risk. Therefore, if increased risk is suspected in a
subset of the population, analyses should be stratified.
Conclusions
Ecological methods can be useful in assessment of vaccine safety but it is important for investi-
gators to understand the impacts of masking by strata not at risk, patterns of onset and diagno-
sis, and vaccine coverage. What appears to be an estimate of no effect could be valid or, as
shown in our simulations, could be an underestimation.
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